Trium Capital’s Esperion Therapeutics ESPR Stock Holding History

Trium Capital’s Portfolio ESPR Stock Details ESPR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	–	Sell	-11,158,150	Closed	-$35.3M	–	56
2026 Q2	$35.3M	Buy	+11,158,150	New	+$31.2M	21.69%	2

Trium Capital's ESPR Position: Q3 2026 in Review

Trium Capital sold out of Esperion Therapeutics (ESPR) in Q3 2026, closing a stake of 11,158,150 shares — an estimated $35.3M sold.

Trium Capital first reported a position in ESPR in Q2 2026 and held it in 1 quarter. The position peaked at $35.3M in Q2 2026. 0 funds tracked by Wall St. Rank hold ESPR as of Q3 2026.

Trium Capital reported no remaining Esperion Therapeutics position as of Q3 2026 after selling out during the quarter.
Trium Capital sold 11,158,150 Esperion Therapeutics shares in Q3 2026, an estimated $35.3M.
Trium Capital first reported a position in Esperion Therapeutics in Q2 2026 and held it in 1 quarter.
Trium Capital's Esperion Therapeutics position peaked at $35.3M in Q2 2026.
0 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q3 2026.

Based on Trium Capital's 13F filing for Q3 2026, filed 16 Oct 2026.